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Abstract: The purpose of this study was to compare chemotherapy-naive patients with stage 
IV nonsmall cell lung cancer patients treated with chemotherapy or chemoimmunotherapy. We 
tested doxetacel plus cisplatinum as chemotherapy protocol. An immunomodulatory adjuvant 
system was added as chemoimmunotherapy to the previously mentioned protocol. This system 
contains three well-known and complementary conditioners of protective immune-responses: 
cyclophosphamide low-dose, granulocyte macrophage-colony stimulant factor and magnesium 
silicate granuloma. Eighty-eight patients were randomly assigned to receive every 3-weeks one 
of the treatments under comparison. Patients received four cycles of treatment unless disease 
progression or unacceptable toxicity was documented. The maximum follow-up was one year. In 
each arm, tumor response (rate,duration), median survival time, 1-year overall survival, safety, 
and immunity modiﬁ  cations were assessed. Immunity was evaluated by submitting peripheral 
blood mononuclear cells to laboratory tests for nonspeciﬁ  c immunity: a) phytohemaglutinin-
induced lymphocyte proliferation, b) prevalence of T-Regulatory (CD4+CD25+) cells and for 
speciﬁ  c immunity: a) lymphocyte proliferation induced by tumor-associated antigens (TAA) 
contained in a previously described autologous thermostable hemoderivative. The difference 
(chemotherapy vs. chemoimmunotherapy) in response rate induced by the two treatments 
(39.0% and 35.0%) was not statistically signiﬁ  cant. However, the response duration (22 and 
31 weeks), the median survival time (32 and 44 weeks) and 1-year survival (33.3% and 39.1%) 
were statistically higher with chemoimmunotherapy. No difference in toxicity between both 
arms was demonstrated. A switch in the laboratory immunity proﬁ  le, nonspeciﬁ  c and speciﬁ  c, 
was associated with the chemoimmunotherapy treatment: increase of proliferative lymphocyte 
response, decrease of tolerogenic T-regulatory cells and eliciting TAA-sensitization.
Keywords: lung cancer chemotherapy, lung cancer chemoimmunotherapy, cancer vaccine, 
immunomodulatory cancer treatment, immunotherapy adjuvants, cancer therapy
Introduction
Despite aggressive treatment with surgery, radiation and chemotherapy, lung cancer is 
the leading cause of cancer mortality, resulting in more than 160,000 deaths per year 
in the United States and 1.2 million worldwide. Nonsmall cell lung cancer (NSCLC) 
accounts for approximately 80% of all lung cancers (ALA 2005).
The treatment of advanced stages of lung cancer with systemic chemotherapy has 
obtained modest results (Socinski et al 2003). Immunotherapy, another systemic treat-
ment, also has been disappointing since the historic intents with BCG (bacille Calmette 
Guérin; Hadźiev et al 1982), Corynebacterium parvum (Issell et al 1978), and thymosin 
(Chretien et al 1979) up to the recent trials with humanized antibodies targeting speciﬁ  c 
tumor-associated antigens (Lynch et al 2004). However, in last years, new platforms 
for chemotherapy as tumor antigens releaser and immunotherapy as immunomodula-
tory conditioner have introduced a rational for the association of these platforms in a Biologics: Targets & Therapy 2008:2(3) 556
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chemoimmunotherapy protocol in order to improve the results 
of advanced NSCLC treatment.
In fact, chemotherapy is a tumor antigens releaser. 
In malignant disease spontaneously progressing, without 
treatment, the content of dying tumor cells is transferred to 
the interstice, to the lymph and to the blood. Some compo-
nents of that content are tumor-associated antigens (TAA). 
This malignant tumor content, released from dying cells, 
meets the immune system in the interstice, in the lymph, and 
also in the circulating blood. This mechanism can work as a 
spontaneous endogenous vaccination. However, it is evident 
the failure of tumor immune control by this spontaneous 
endogenous vaccination in progressive cancer. This failure 
could be result of the low antigenicity of TAA released 
from spontaneous apoptotic tumor cells death (Melcher 
et al 1998) and the conditioning of tolerogenic or permis-
sive immune response induced during the carcinogenesis 
(Cochran et al 2006). Apoptotic tumor cell death increases 
when malignant disease is submitted to oncological treat-
ments, mainly chemotherapy. Cell death through apoptosis is 
less immunogenic than cell death through necrosis (Melcher 
et al 1999). However, the immunogenicity is maintained 
when apoptosis follows a cellular stress (Feng et al 2002) as 
it is produced by chemotherapy (Tiligada 2006). Therefore, 
chemotherapy works, at least partially, as an endogenous 
vaccination enhancer with high efﬁ  cacy as releaser of TAA 
antigens, one of the components in the conﬁ  guration of cancer 
vaccines (Raez 2005).
Immunomodulatory conditioning is a new platform 
of immunotherapy. The goal is to switch the tolerogenic 
(permissive) tumor-induced conditioning of the immune 
responses to immunogenic (protective) immune responses 
(Pinedo et al 2000; Rini et al 2005). A tool to accomplish 
this goal is the described systemic depletion of tolerogenic 
T-regulatory cells population (CD4+CD25+) by cyclophos-
phamide at low dose, injected a short period (three days) 
before antigen stimulation (Berd et al 1982; Ghiringhelli 
et al 2004). Another tool is the recently described immuno-
therapeutic site (ITS), where different immunomodulatory 
agents are injected in order to induce in the draining lymph 
node an increase of activated antigen-presenting cells and 
a depletion of tolerogenic T-regulatory cells. This loco-
regional immunomodulation is decisional because it elicits a 
systemic protective lymph nodes conditioning. Among other 
agents (erythrocytes or other local inﬂ  ammatory agents) to 
create an ITS, magnesium silicate that produces a subcuta-
neous granuloma (MSG) was reported as a strong inducer 
of remote macrophage activation with enhancement of 
protective antitumor immune responses, when it is performed 
during the 4 days previous to the antigen (Fauve and Hevin 
1977; Fontan et al 1983, 1992; Fauve et al 1987). It was also 
reported that granulocyte macrophage-colony stimulating 
factor (GM-CSF), injected subcutaneously, simultaneously 
or around the time of antigen stimulation, is a recruiter and 
activator of antigen presenting cells, mainly dendritic cells 
(Disis et al 1996; Dranoff 2002).
Brieﬂ  y, the association of systemic low-dose cyclophos-
phamide and a locoregional lymph node immunomodulation 
by MSG and GM-CSF is a safe immunomodulatory adjuvant 
system (IAS) of cancer vaccines supported by the proven 
properties of their components and evidenced in previous 
clinical trials (Garcia-Giralt et al 2006, 2007; Lasalvia-
Prisco et al 2007a, 2007b, 2007c). This study compared in 
advanced NSCLC, the antitumoral and immunological effects 
of the standard chemotherapy and chemoimmunotherapy 
designed using the same chemotherapy in its platform of 
tumor antigens releaser and the platform of immunomodu-
latory conditioning immunotherapy through and IAS with 
cyclophosphamide, MSG, and GM-CSF.
Patients and methods
Patients and trial
Patients were submitted to a randomized phase II study. The 
trial accomplished the ﬂ  ow diagram and checklist of the 
CONSORT statement in conjunction with the CONSORT 
explanation and elaboration document (Altman et al 2001; 
Moher et al 2001).
The patient’s characteristics are summarized in Table I. 
Eighty-eight patients who met the following eligibility criteria 
Table 1. Patients’ characteristics
Characteristic CHT  CHIMT  Number  of
    Patients
Included  44 44 88
Assessable  41 40 81
Male  33 34 67
Female 8  6  14
Median Age  56  58
Age Range  40–73  33–74 
Weight loss 5% 48.8%  55.0%
Squamous cell  36.6% (15)  40.0% (16)
Large cell  24.4% (10)  22.5% (9) 
Adenocarcinoma  29.3% (12)  25.0% (10)
Not otherwise speciﬁ  ed  9.8% (4)  12.5% (5)
Notes: Stage IV NSCLC randomized in two arms: CHT, treated with chemotherapy 
(doxetacel + cisplatinum) and CHIMT.  Performance status 2. No prior chemotherapy, 
radiotherapy or surgery. No brain metastasis.
Abbreviations: CHT, treated with chemotherapy (doxetacel + cisplatinum); CHIMT, 
treated with same chemotherapy + an immunomodulatory adjuvant system (IAS).Biologics: Targets & Therapy 2008:2(3) 557
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were included. The criteria were: histopathologically conﬁ  rmed 
diagnosis of inoperable NSCLC (stage IV); age 75 years; 
Eastern Cooperative Oncology Group performance status 
(Oken et al 1982) 2; no prior malignancy, chemotherapy, 
surgery, or radiotherapy; no central nervous system metas-
tases and at least one measurable lesion; tumor burden com-
prising no more than 3 metastasis sites; no associated acute 
disease. Conservation of organic functions was conﬁ  rmed 
(adequate bone marrow function: WBC 3000/mm3, 
ANC 1500/mm, Hgb 9.0 g/dl, and platelets 100,000/mm3; 
adequate liver function: bilirubin 1.5 mg/dl, aspartate 
aminotransferase 40 IU/L; adequate kidney function: 
creatinine 1.5 mg/dl). The study was conducted in patients 
admitted to medical centers that submitted medical data 
to the Cooperative Trials Center (CTC) of Interdoctors 
Medical Procedures, Florida, USA (Interdoctors Medical 
Procedures is a nonpharmaceutical concern group sup-
porting scientiﬁ  c research in medical procedures). Written 
informed consent was obtained from all patients included in 
the study. The Institutional Review Board (IRB) approved 
the trial, which complied with the Declaration of Helsinki 
(WMA 1997). In a prospective, randomized, controlled 
trial, the treating physicians did not participate in the arm 
randomization for their patients. The patients were ran-
domized into 2 groups that received different treatments: 
chemotherapy (CHT) or chemoimmunotherapy (CHIMT). 
Basically, CHIMT is CHT with the IAS associated to each 
chemotherapy series.
Chemotherapy
CHT protocol was one of the therapeutic options recom-
mended in the PDQ (Physician Data Query) database of the 
National Cancer Institute for Stage IV, NSCLS: doxetacel 
plus cisplatinum (Georgoulias et al 2004). Brieﬂ  y, doxetacel 
100 mg/m2 on day 1, and cisplatinum 80 mg/m2 on day 2. 
The series were repeated every 3 weeks.
Immunomodulative adjuvant system
IAS was added to the study design (CHIMT arm) in 
each chemotherapy series, considering day 2 as the 
start day of tumor cell affectation by chemotherapy. 
Cyclophosphamide 300 mg/m2 was administered on day-
1 of each series; GM-CSF 300 μg SC was administrated 
days 2 to 5, daily, of each series and .a subcutaneous 
granuloma was induced with 500 mg magnesium silicate 
on day-2 of each series.
A maximum of 4 series of CHT or CHIMT were 
programmed.
Assessment
In all patients, data was collected at baseline and followed 
until death, loss of follow-up, or until a maximum of one 
year.
Overall tumor response and safety were documented 
8 weeks after completion of treatment. The overall response 
rate was expressed as the proportion of patients demonstrat-
ing CR (complete remission) or PR (partial remission) based 
on all patients randomly assigned to receive treatment and 
according to the response evaluation criteria in solid tumors 
(RECIST). All responses required conﬁ  rmation at least four 
weeks after they were ﬁ  rst observed (Therasse et al 2000).
Response duration (RD) was calculated from the ﬁ  rst 
date of a 50% reduction in the tumor was registered to the 
last date that tumor reduction was documented.
At the end of the follow-up (1 year), survival parameters 
were analyzed for each group using the Kaplan-Meier method 
from the ﬁ  rst day of treatment to death or the date of the last 
follow-up visit for patients who were still alive. Median time 
survival (MTS) and one year overall survival (1-OS) were 
estimated. Assessment of safety was based on reports of 
adverse events, laboratory-test results, and vital-sign mea-
surements. Adverse events were categorized according to 
the common toxicity criteria of the National Cancer Institute 
(CTCAE), version 2 (NCI 2006).
Laboratory tests
The laboratory tests were designed taking in account pre-
liminary assays in patients treated with each component of 
IAS, showing accumulative increase of peripheral blood 
monomolecular cells (PBMC) proliferation responses to 
phytohemaglutinin (PHA) and decrease of T-regulatory cells 
(results not shown) supporting the use of the associated three 
IAS components in this study.
In a sample of PBMC, lymphocyte proliferation assay 
induced with PHA and T-regulatory Cells (CD4+CD25+) 
prevalence (T-Reg) were assessed as nonspeciﬁ  c immune-
reactivity parameters. It was previously demonstrated that 
an autologous thermostable hemoderivative (ATH) con-
tained TAA (Lasalvia-Prisco et al 2003, 2006a, 2006b); 
therefore, lymphocytes proliferation assay induced with 
this ATH was evaluated as speciﬁ  c assay for immunity 
against circulant TAA.
Isolation of PBMC
Heparinized blood was diluted 1/1 v/v with phosphate buf-
fer solution (PBS) before Ficoll density centrifugation. The 
buffy coat containing PBMC was harvested, contaminating Biologics: Targets & Therapy 2008:2(3) 558
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red blood cells lysed by incubating in ACK-lysing buffer 
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4), 
and washed twice in cold PBS. A PBMC sample in each 
patient was prepared at days-3, 3 and 20 of the ﬁ  rst treat-
ment series.
PHA and ATH lymphocyte proliferation 
assay
PHA was obtained from Sigma (St. Louis, MO). For each 
test, a fresh ATH was prepared as it was described (Lasalvia-
Prisco et al 2003).
PHA and ATH lymphocyte proliferation assays were 
made immediately after obtaining each sample of PBMCs, 
days-3, 3 and 20 by incubating 105 PBMCs, from an aliquot of 
PBMC sample obtained as mentioned above, added to 100 μl 
of RPMI 1640 with 10% human AB serum and deposited in 
round-bottomed wells on a 96-well plate. Two immunologic 
challenges and appropriate controls were tested in triplicate: 
a) Medium control in the top row, an additional 100 μl of 
working RPMI 1640 medium; b) PHA, 100 μl of a serial 
dilution of stock PHA (0.5 mg/ml) in RPMI 1640 (1:10, 
1:100 and 1:500) was placed in triplicate wells of the ﬁ  rst 
9 wells of the second row; c) ATH, 100 μl of a serial dilution 
of ATH (10x concentrate from 20 mL blood) in RPMI 1640 
(1:10, 1:100 and 1:500) was placed in triplicate wells of the 
ﬁ  rst 9 wells of the third row; d) Negative control, 100 μl of 
l:100 dilution of healthy male plasma in RPMI 1640 medium 
was added to each of ﬁ  rst 3 wells of the forth row. RPMI 
1640 were also obtained from Sigma. Plates were incubated 
in a 5% CO2 incubator at 37 °C for 5 days. One microcurie 
of tritiated thymidine was then added to each well in a vol-
ume of 20 μl and plates were again incubated, at 37 °C for 
16 h. The content of each well was harvested and counted 
in a liquid scintillation beta-counter. The mean of the three 
determinations per point was registered as mean-cpm of 
each challenger. The mean-cpm of the negative control was 
divided by the mean-cpm of the media control. If this ratio 
was less than 2.00, then the negative control was accepted. 
For each test in each patient, the mean-cpm of the PHA dilu-
tion with the highest cpm was divided by the mean of the 
media control, expressed as % of the value calculated for the 
day -3 and deﬁ  ned as PHA lymphocyte proliferation response 
(PHA-LPR). Also for each test in each patient, the mean-cpm 
of the ATH dilution with the highest cpm was divided by the 
mean-cpm of the media control expressed as a percentage 
of the value calculated for the day -3 and deﬁ  ned as ATH 
lymphocyte proliferation response (ATH-LPR). The results 
were statistically compared in both treatment arms.
T-regulatory (CD4+CD25+) prevalence
An aliquot of each PBMC sample, days-3, 3 and 20, isolated 
from peripheral blood, were used for two and three color 
cell surface labeling using Abs against CD4 and CD25. We 
analyzed the cell samples by ﬂ  ow cytometry after cell surface 
labeling for co-expression of CD4 and CD25 molecules. The 
prevalence of CD4+CD25+ cells as a percentage of total 
CD4+ population was determined by standard determination 
of quadrant statistics and registered as T-regulatory cells 
value (T-reg ). For each test, days-3, 3 and 20, in each patient, 
T-reg values were expressed as percent of the day -3 mean 
values and deﬁ  ned as T-reg response (T-regr). The results in 
both treatment arms were statistically compared.
Statistical analysis
Response rate to treatment (RR), response duration (RD), 
median survival time (MST), and 1-OS were the primary 
end-point. Secondary end-points included safety and labo-
ratory tests.
Survival rates at 95% conﬁ  dence intervals (CIs) were 
estimated and the comparisons between the two treatment 
procedures were carried out using the two-tailed log-rank test. 
The sample size for survival (log-rank) was assessed using 
the approach of Schoenfeld and Richter. RR in both groups 
was compared using Fisher’s exact test. RD difference was 
evaluated using the generalized Wilcoxon test. Results of the 
laboratory tests (PHA LPR, ATH LPR, and T-regr) in the two 
arms were statistically compared by unpaired Student’s t-test. 
Statistical analysis was performed with WINKS Statistical 
Data Analysis (SDA) software (TexaSoft, Cedar Hill, TX).
Results
Eighty-eight patients who met the eligibility criteria were 
accrued into the study; 44 patients were randomly assigned 
to each treatment arm, CHT and CHIMT. Eighty-one patients 
were assessable, 41 in CHT arm and 40 in CHIMT arm. Seven 
patients were nonassessable because of unrelated intercur-
rent diseases (4 patients), refused further treatment after one 
chemotherapy series (2 patients), and nonaccomplishing 
follow-up (1 patient).
Patient characteristics are listed in Table 1.
The treatment arms, CHT and CHIMT, were balanced 
with respect to the clinical prognosis parameter, respectively. 
The median age was 56 and 58 (range 40 to 73 and 33 to 
74 years); at least 5% weight loss (48.8% and 55.0%); cell 
type was squamous cell carcinoma in 15 and 16 patients 
(36.6% and 40.0%), large cell in 10 and 9 patients (24.4% 
and 22.5%), adenocarcinoma in 12 and 10 patients (29.3% Biologics: Targets & Therapy 2008:2(3) 559
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and 25.0%), and not speciﬁ  ed in 4 and 5 patients (10.0% 
and 12.5%).
Table 2 shows the analysis of tumor response in both 
arms.
RD was 39.0% (1 patient with CR and 15 patients with 
PR) in CHT arm and 35.0% (14 patients with PR) in CHIMT 
arm. The difference in response was not statistically signiﬁ  -
cant (p = 0.12).
RD was 22 weeks in CHT arm and 31 weeks in CHIMT 
arm. This difference was signiﬁ  cant (p  0.05).
Figure 1 shows the survival parameters in the two treat-
ment arms.
The values of MST and 1-OS: in CHT and CHIMT 
arms, MSTs were 32 and 44 weeks, respectively; 1-OS were 
33.3% and 39.1%, respectively. Figure 1 also shows overall 
survival curves for the two treatment arms. The log rank 
test showed a statistical signiﬁ  cant difference between the 
survival curves favorable to CHIMT versus CHT (p = 0.02). 
The sample size was small but reached a power of 80% for 
an alpha value of 0.05%.
No different toxicity according CTCAE (NCI 2006) 
between CHT and CHIMT was evident. The most signiﬁ  cant 
(grade 3/4) toxicities found included, respectively: nausea 
(7 and 5 cases), hypertension (4 and 3 cases), diarrhea 
(1 and 2 cases), dyspnea (1 and 0 cases), neurosensory toxic-
ity (3 and 5 cases), hypomagnesaemia (1 and 1 cases), and 
neutropenia (7 and 5 cases).
Table 3 shows the PBMC tests results.
The mean ± SD of PHA-LPR was signiﬁ  cant higher in 
CHIMT posttreatment samples, day 20, than in CHIMT 
pretreatment samples, day -3. No signiﬁ  cant difference was 
in evidence in PHA-LPR day 3 and day -3 of CHIMT treat-
ment. No signiﬁ  cant difference found in CHT tests.
The mean ± SD of T-regr prevalence was a mirror image of 
PHA-LPR. It was lower in CHIMT posttreatment samples, day 
20, than in CHIMT pretreatment samples, day -3. No signiﬁ  cant 
difference in T-reg day -3 and day 3 of CHIMT treatment was 
in evidence. No signiﬁ  cant difference found in CHT tests.
The mean ± SD of ATH-LPR was also higher in CHIMT 
posttreatment latest samples, day 20, than in CHIMT pre-
treatment samples, day -3. However, there was a small sig-
niﬁ  cant difference of higher values in early posttreatments 
tests, day 3, versus pretreatment tests, day -3 in both, CHT 
and CHIMT arms. No signiﬁ  cant variation was found in late 
CHT posttreatments tests, day 20.
Discussion
This study of an innovative therapeutic platform reports 
exhaustively from previous own and independent references 
supporting the rational of this procedure.
The patients in the two arms were comparable in the 
considered prognostic parameters (Table 1). The sample 
size was acceptable according to the approach of Schoenfeld 
and Richter and it also accomplished the criteria recently 
reported for the two-arm design of phase II clinical trials 
(Taylor et al 2006). The RRs were statistically nondifferent 
between CHM and CHIMT and the values are in the range of 
RR reported in similar medical conditions treated only with 
Table 2. Overall tumor response
 CHT  (n  = 41)  CHIMT (n = 40) 
CR 1  0 
PR 15  14 
Stable disease  3  4 
Progressive disease  25  23 
Not assessable patients  3  4 
Assessable patients  41  40 
Response (CR + PR)     p
% Response  39.0  35.0  =.12
Response duration (weeks)  22  31  0.05
Abbreviations: CR, complete response; PR, partial response.
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Figure 1. Stage IV nonsmall cell lung cancer at one-year follow-up. Observed survival in 
the chemotherapy arm (CHT; 41 patients): Doxetacel + cisplatinum and the chemoim-
munotherapy arm (CHIMT; 40 patients): CHT + immunomodulatory adjuvant system. 
Survival rates at 95% conﬁ  dence intervals (CIs) were estimated and the comparisons 
between the two treatment procedures were carried out using the two-tailed log-rank 
test. P-value for log-rank test was calculated. The sample size for Survival (log-rank) 
was assessed using the approach of Schoenfeld and Richter.
Abbreviations: MST, median survival time; 1-OS, one year overall survival.Biologics: Targets & Therapy 2008:2(3) 560
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comparable chemotherapy (Socinski et al 2003). We infer 
that the tested immunomodulatory adjuvant had no inﬂ  uence 
upon the initial response to chemotherapy. Differently, the 
duration of response and the survival parameters were all 
statistically increased in CHIMT compared with CHT. This 
increment is also evident if we compare CHIMT results 
with the previously reported same parameters in trials of 
comparable patients treated with comparable chemotherapy 
(Socinski et al 2003). We deduce that the tested immuno-
modulatory adjuvant elicits a mechanism that maintains 
the response to chemotherapy. The statistically signiﬁ  cant 
increase of PHA-LPR and the signiﬁ  cant decrease of T-reg 
are compatible with a switch of the immune system, condi-
tioning the immune responses from the permissive (tolero-
genic) to the protective (immunogenic). These facts concur 
with the reported immunomodulatory activity of the IAS 
components: Cyclophosphamide, low dose, 3 days before 
antigen stimulation, decreases the CD4+CD25+ (T-reg) cell 
population (Berd et al 1982; Ghiringhelli et al 2004). The 
magnesium silicate granuloma has been demonstrated as a 
remote enhancer of systemic macrophage activity committed 
to the protective responses (Fauve and Hevin 1977; Fontan 
et al 1983, 1992; Fauve et al 1987). GM-CSF, subcutane-
ously, administered around the antigenic stimulation, recruits 
and activates the antigen presenting cells, mainly dendritic 
cells, allowing a stronger immune response (Disis et al 1996; 
Dranoff 2002).
The inﬂ  uence of this nonspeciﬁ  c immunity modulation 
upon the speciﬁ  c antitumor immunity is suggested by the 
results of ATH-LPR. The early increase of ATH-LPR at day 3, 
in both arms, CHT and CHIMT, is compatible with higher 
release of TAA induced by chemotherapy and recovered 
in the contemporary ATH. The most important increase of 
ATH-LPR, evidenced at day 20, is exclusive of CHIMT and 
is associated with the immunity nonspeciﬁ  c modulation. We 
interpret that chemotherapy-induced apoptosis produced 
an immunogenic TAA release from tumor cells, impacting 
upon an immune system that could be conditioned by IAS 
to elicit protective responses, resulting in an immunotherapy 
mechanism added to the chemotherapy antitumor effect. The 
antitumor response duration and the survival parameters are 
higher in CHIMT arm than in CHT arm. This result is com-
patible with a protracted antitumor effect of chemotherapy 
plus immunotherapy, which delays the recovery of tumor 
growth after remission induced by cytotoxic drugs.
Conclusion
CHT and CHIMT resulted in a not-different RR but CHIMT 
maintained the cancer control safely for a longer period, 
improving RD, MST, and 1-OS compared with CHT. The 
immunity-associated changes are compatible with a poten-
tiation of the time-effective chemotherapy-antitumor-effect 
through an internal vaccination by TAA (released from 
chemotherapy-induced tumor cells apoptosis) impacting 
upon a modulated proprotective/antipermissive immune 
system. Despite the small number of cases of this phase II 
study, the statistical signiﬁ  cance evidenced warrants further 
investigations in order to assess the clinical relevance of this 
chemo-immunotherapy.
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